Suppr超能文献

人中性粒细胞通过 trogocytosis 而非吞噬作用来介导与抗 CD20 抗体包被的 CLL B 细胞的结合。

Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.

机构信息

Center of Cellular Therapy G. Lanzani, Division of Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.

Department of Biomedical Engineering, Istituto di Ricerche Farmacologiche Mario Negri, Istituto di Ricovero e Cura a Carattere Scientifico, Bergamo, Italy; and.

出版信息

Blood. 2017 May 11;129(19):2636-2644. doi: 10.1182/blood-2016-08-735605. Epub 2017 Mar 13.

Abstract

Polymorphonuclear neutrophils (PMNs) have previously been reported to mediate phagocytosis of anti-CD20-opsonized B cells from patients with chronic lymphocytic leukemia (CLL). However, recent data have suggested that PMNs, like macrophages, can also mediate trogocytosis. We have performed experiments to more precisely investigate this point and to discriminate between trogocytosis and phagocytosis. In live-cell time-lapse microscopy experiments, we could not detect any significant phagocytosis by purified PMNs of anti-CD20-opsonized CLL B cells, but could detect only the repeated close contact between effectors and targets, which suggested trogocytosis. Similarly, in flow cytometry assays using CLL B-cell targets labeled with the membrane dye PKH67 and opsonized with rituximab or obinutuzumab, we observed that a mean of 50% and 75% of PMNs had taken a fraction of the dye from CLL B cells at 3 and 20 hours, respectively, with no significant decrease in absolute live or total CLL B-cell numbers, confirming that trogocytosis occurs, rather than phagocytosis. Trogocytosis was accompanied by loss of membrane CD20 from CLL B cells, which was evident with rituximab but not obinutuzumab. We conclude that PMNs mediate mostly trogocytosis rather than phagocytosis of anti-CD20-opsonized CLL B cells, and we discuss the implications of this finding in patients with CLL treated with rituximab or obinutuzumab in vivo.

摘要

多形核粒细胞 (PMN) 先前已被报道介导吞噬作用从慢性淋巴细胞白血病 (CLL) 患者的抗 CD20 调理 B 细胞。然而,最近的数据表明,PMN 与巨噬细胞一样,也可以介导 trogocytosis。我们进行了实验来更精确地研究这一点,并区分 trogocytosis 和吞噬作用。在活细胞时间 lapse 显微镜实验中,我们不能检测到任何明显的吞噬作用由纯化的 PMN 抗 CD20 调理 CLL B 细胞,但只能检测到效应器和靶细胞之间的反复密切接触,这表明是 trogocytosis。同样,在使用膜染料 PKH67 标记的 CLL B 细胞靶标和利妥昔单抗或奥滨尤妥珠单抗调理的流式细胞术测定中,我们观察到,平均 50%和 75%的 PMN 在 3 小时和 20 小时分别从 CLL B 细胞中摄取了一部分染料,而活细胞或总 CLL B 细胞数量没有明显减少,证实了 trogocytosis 的发生,而不是吞噬作用。Trogocytosis 伴随着 CLL B 细胞膜 CD20 的丢失,这在利妥昔单抗中很明显,但在奥滨尤妥珠单抗中则不然。我们得出结论,PMN 主要介导抗 CD20 调理的 CLL B 细胞的 trogocytosis,而不是吞噬作用,我们讨论了这一发现在利妥昔单抗或奥滨尤妥珠单抗体内治疗 CLL 患者中的意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验